Compare DTSS & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTSS | ADVB |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | Hong Kong |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.6M |
| IPO Year | 2026 | 2023 |
| Metric | DTSS | ADVB |
|---|---|---|
| Price | $0.55 | $4.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 281.2K | 13.4K |
| Earning Date | 10-05-2026 | 10-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3431.25 |
| EPS | N/A | ★ 5.33 |
| Revenue | N/A | ★ $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $3.66 |
| 52 Week High | $2.29 | $113.80 |
| Indicator | DTSS | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 37.08 |
| Support Level | N/A | $3.86 |
| Resistance Level | $0.98 | $5.59 |
| Average True Range (ATR) | 0.07 | 0.53 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 3.70 | 36.67 |
Datasea Intelligent Technology Ltd, formerly known as Datasea Inc, is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.